Corsini E, Dykstra C, Craig W A, Tidwell R R, Rosenthal G J
Immunotoxicology Section, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709.
Immunol Lett. 1992 Dec;34(3):303-8. doi: 10.1016/0165-2478(92)90228-g.
Pneumocystis carinii, and the inflammatory response it provokes, together contribute to irreversible lung damage in immunocompromised patients. P. carinii cysts were found to be capable of inducing tumor necrosis factor-alpha (TNF) release from alveolar macrophages in a concentration-dependent manner. At physiologically achievable concentrations, pentamidine isethionate (pentamidine) substantially reduces such production. Pretreatment of alveolar macrophages (AM phi) with interferon-gamma (IFN-gamma) synergizes with P. carinii to produce increased levels of TNF, a condition which pentamidine was also able to antagonize. Pentamidine treatment did not interfere with the phagocytic ability of AM phi. Considering clinical reduction of TNF could lessen P. carinii pneumonia (PCP) induced inflammation, the efficacy of pentamidine in the treatment of PCP may be partially associated with its ability to inhibit the release of inflammatory mediators such as TNF.
卡氏肺孢子虫及其引发的炎症反应共同导致免疫功能低下患者出现不可逆的肺损伤。已发现卡氏肺孢子虫囊肿能够以浓度依赖的方式诱导肺泡巨噬细胞释放肿瘤坏死因子-α(TNF)。在生理可达到的浓度下,乙磺半胱氨酸喷他脒(喷他脒)可显著减少此类产生。用γ干扰素(IFN-γ)预处理肺泡巨噬细胞(AM phi)可与卡氏肺孢子虫协同作用,产生更高水平的TNF,而喷他脒也能够拮抗这种情况。喷他脒治疗并不干扰AM phi的吞噬能力。考虑到临床上降低TNF可减轻卡氏肺孢子虫肺炎(PCP)引发的炎症,喷他脒治疗PCP的疗效可能部分与其抑制TNF等炎症介质释放的能力有关。